TLX Telix Pharmaceuticals Limited

P/E 112.9
Forward P/E 161.29
Price/Sales 4.306
Beta 0.6
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 Telix Pharmaceuticals is trading 5.47% up in after-hours trading — reason remains unconfirmed

Telix Pharmaceuticals is trading 5.47% up at $11.91 after rising from the August 28 regular-session close of $11.29; the reason remains unconfirmed. -...

🔴 Telix Pharmaceuticals is trading 4.41% down today

Telix Pharmaceuticals is trading 4.41% down at $11.18, based on live price context for August 26, 2026; no clearly dated company announcement was identified as...

🔴 Telix Pharmaceuticals is trading 9.2% down today as potential share issuance raises dilution concerns

Telix Pharmaceuticals is trading 9.2% down at $11.31 after investors reacted negatively to the August 20 announcement of a potential at-the-market equity...

Telix Posts Blowout Earnings, So Why Did Investors Punish the Stock 7% on Dilution Fears

Telix Posts Blowout Earnings, So Why Did Investors Punish the Stock 7% on Dilution Fears

Shares shifted sharply lower on August 21, with Telix Pharmaceuticals (NASDAQ: TLX) falling 7.2% to $11.53 despite reporting half-year results that, on their...

🔴 Telix Pharmaceuticals is trading 7.17% down in pre-market on dilution concerns over new ADS issuance

Telix Pharmaceuticals is trading 7.17% down in pre-market at $11.53 after announcing an at-the-market facility allowing issuance of new ADSs, raising potential...

🟢 Telix Pharmaceuticals is trading 4.6% up in pre-market

Telix Pharmaceuticals is trading at $12.27, up 4.60%, with no clearly reported company-specific catalyst on August 18, 2026. - Half-year results are scheduled...

🔴 Telix Pharmaceuticals is trading 6.7% down in pre-market — no clear catalyst identified

Telix Pharmaceuticals is trading 6.7% down at $11.03 after falling from its August 14, 2026 close of $11.82, with no clear company-specific catalyst identified...

🔴 Telix Pharmaceuticals is trading 6.7% down today in pre-market — no clear catalyst identified

Telix Pharmaceuticals is trading 6.7% down now in pre-market at $11.03 after falling from its August 14 close of $11.82; no clear company-specific catalyst has...

🔴 Telix Pharmaceuticals is trading 6.7% down in pre-market with no clear company-specific catalyst

Telix Pharmaceuticals is trading 6.7% down at $11.03, with no clear company-specific announcement explaining the pre-market decline. - Shares fell from the...

🔴 Telix Pharmaceuticals is trading 4% down today with no clear company-specific catalyst

Telix Pharmaceuticals is trading 4.02% down at $11.83, with no clear company-specific catalyst emerging on August 14, 2026. - The latest investor update...

🔴 Telix Pharmaceuticals is trading 5.3% down in pre-market with no clear company-specific catalyst

Telix Pharmaceuticals is trading at $11.68, down 5.25% in pre-market, with no clear company-specific announcement explaining the decline. - The company last...

Telix Rallies 8% on an Event Invite — Can a Pipeline Showcase Justify a $16-Per-Day Run-Up With No New Data?

Shares surged as Telix Pharmaceuticals announced a September research showcase in New York, capping a 16.6% climb from $9.89 to $11.53 over five trading days —...

🟢 Telix Pharmaceuticals is trading 8% up today after announcing its September 22 R&D Day

Telix Pharmaceuticals is trading 8.41% up at $11.53 after announcing its September 22, 2026 R&D Day in New York. - The event will highlight therapeutic and...

🟢 Telix Pharmaceuticals is trading 8% up today after announcing a September 22 R&D Day

Telix Pharmaceuticals is trading 8.41% up at $11.53 after announcing its September 22, 2026 R&D Day in New York. - The event will cover its therapeutic and...

🟢 Telix Pharmaceuticals is trading 5% up in pre-market after announcing September 22 R&D Day

Telix Pharmaceuticals is trading 5.26% up at $11.20 after announcing on August 6, 2026, that it will host an R&D Day in New York on September 22. - The event...

🔴 Telix Pharmaceuticals is trading 5.1% down

Telix Pharmaceuticals is trading at $10.37, down 5.1% from a comparison close of $10.92 during regular trading. This is a price-action follow-up, so a separate...

🟢 Telix Pharmaceuticals is trading 4.05% up today on strong Q2 revenue growth and pipeline progress

Telix Pharmaceuticals is trading at $10.94 (+4.05%) following a strong Q2 2026 update and positive guidance outlook. • Quarterly revenue reached US$247...

🟢 Telix Pharmaceuticals is trading 4.2% up today on strong Q2 revenue growth and pipeline progress

Telix Pharmaceuticals is trading at $10.95, up 4.2% today, after investors digested a strong quarterly performance and clinical pipeline update. - The company...

Telix Advances Illuccix in Japan, Opens New Melbourne Production Site

Telix Advances Illuccix in Japan, Opens New Melbourne Production Site

Telix Pharmaceuticals completed patient enrollment for its Phase 3 registration study of Illuccix in Japan. The study evaluates the efficacy and safety of...

🔴 Telix Pharmaceuticals is trading 4.8% down today amid profit-taking and consolidation

Telix Pharmaceuticals is trading 4.8% down today at $10.32 amid profit-taking and short-term consolidation following a period of strong gains and heightened...